Streetbeat News

Regulatory

GCI

GETY

Global news and publishing organizations have signed an open letter proposing principles for the regulated and responsible growth of generative AI models. The letter outlines regulatory and industry actions to protect the content powering AI applications and preserve public trust in media. Signatories include Agence France-Presse, European Pressphoto Agency, European Publishers' Council, Gannett | USA TODAY Network, Getty Images, National Press Photographers Association, National Writers Union, News Media Alliance, The Associated Press, and The Authors Guild.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 12:59 pm

AVNS

Trading of Avanos Medical shares has been halted due to pending news.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 12:43 pm

AGEN

SaponiQx has announced successful production of STIMULON cpcQS-21, a cultured plant cell adjuvant with confirmed biochemical comparability to traditional bark extract-derived adjuvant. The company has submitted a Master File for STIMULON cpcQS-21 to the U.S. FDA for reference by partners as part of regulatory submissions. SaponiQx is also collaborating with Ginkgo Bioworks to drive innovation in its adjuvant pipeline through generative molecular design.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 12:40 pm

TTOO

T2 Biosystems, Inc. (NASDAQ:TTOO) has regained compliance with the NASDAQ's market value of listed securities (MVLS) requirement. The company was previously notified of non-compliance due to failure to maintain a MVLS of at least $35 million for 30 consecutive business days. To regain compliance, T2 Biosystems maintained a MVLS of at least $35 million for 10 consecutive trading days. The company must still demonstrate compliance with the Bid Price Rule by November 20, 2023.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 12:39 pm

CPHI

China Pharma Holdings, Inc. (NYSE:CPHI) announced that its subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., has received approval for its candesartan tablets from the National Medical Products Administration of China. The approval indicates that the tablets have passed the quality and efficacy consistency evaluation of generic drugs. Candesartan is used for primary hypertension and is a flagship product of China Pharma. The approval allows the company to participate in China's national centralized procurement, enhancing its competitiveness in government procurement.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 12:38 pm

JAGX

Napo Pharmaceuticals, a subsidiary of Jaguar Health (NASDAQ:JAGX), has submitted a Stage 1 funding application to the Biomedical Advanced Research and Development Authority (BARDA) for the development of NP-300, a drug candidate for the treatment of moderate-to-severe diarrhea, including cholera. The company aims to increase American preparedness and response time in the event of exposure to cholera due to bioterrorism or global warming. Napo's Investigational New Drug (IND) application for NP-300 was activated by the FDA in September 2022.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 12:36 pm

TKNO

Alpha Teknova, Inc. (NASDAQ:TKNO) has announced the opening of a new GMP-certified production facility in Hollister, California. The facility, which recently received ISO 13485:2016 certification, will increase the company's manufacturing capacity for custom, high-quality life sciences reagents. The new facility will enable bioprocessing and gene therapy companies to get into the clinic faster.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 12:25 pm

GOOG

GOOGL

Google, a subsidiary of Alphabet Inc., has proposed to the Australian government that copyright laws should be altered to allow AI systems to gather data from the internet, while providing an opt-out option for publishers who wish to keep their content untouched. This proposal was made in response to a review of AI regulations by the Australian government. The proposed system would be similar to the current 'robots.txt' method, which allows website owners to prevent search engines from accessing parts of their site.

Portfolio Pulse from Sudhanshu Singh

August 09, 2023 | 12:25 pm

DARE

Daré Bioscience has announced positive preliminary efficacy results from its Phase 1/2 clinical study of DARE-HRT1, a treatment for menopausal symptoms, in healthy postmenopausal women. The study found that DARE-HRT1 demonstrated preliminary treatment efficacy for both Vasomotor Symptoms (VMS) and Genitourinary Syndrome of Menopause (GSM). Daré plans to advance DARE-HRT1 into a single Phase 3 efficacy trial for the treatment of VMS due to menopause. If successful, DARE-HRT1 could be the first FDA-approved monthly intravaginal ring delivering both estrogen and progestogen hormone therapy.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 12:24 pm

ELTX

Elicio Therapeutics (NASDAQ:ELTX) has published preclinical data demonstrating that its AMP-CpG adjuvant can induce a potent and durable immune response to Epstein-Barr virus (EBV). The data shows that AMP-CpG directed the trafficking of the vaccine adjuvant into the lymph node to increase the potency of subunit vaccines for inducing T-cells and neutralizing antibodies. The company's near-term focus remains progressing ELI-002, its cancer vaccine candidate for mutant KRAS-driven solid tumors, through the ongoing phase 1 trials and to a randomized trial in pancreatic cancer in 2024.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 12:23 pm